Lilly Endowment Sold Eli Lilly Stock Worth Over $111B in Career Form 4 Value — and December 2025 Was Just the Latest Window

What Happened

Lilly Endowment Inc., the Indianapolis-based private foundation and 10%-plus beneficial owner of Eli Lilly & Co (LLY), filed its latest Form 4 with transactions dated December 29, 2025. Lilly Endowment has been a systematic seller of LLY stock for decades, with career Form 4 filings reporting over $111.8 billion in cumulative sell value across 10,747 transactions.

Why It Matters

Lilly Endowment is one of the largest private foundations in the United States, with assets exceeding $50 billion. The foundation was created by the Lilly family and historically held a concentrated position in Eli Lilly stock. For decades, it has been gradually diversifying — selling LLY shares and redeploying the proceeds into grants and a more diversified investment portfolio.

The selling is not a signal about Eli Lilly’s business prospects. It is mandated by the foundation’s fiduciary duty to diversify and by IRS rules requiring minimum annual distributions. The $111B+ career sell figure reflects the combination of volume (10,747 transactions) and Eli Lilly’s enormous stock price appreciation over decades.

Context

Eli Lilly has been one of the best-performing large-cap pharmaceutical stocks, driven by its GLP-1 weight-loss drug (tirzepatide/Mounjaro) and Alzheimer’s treatment pipeline. The stock traded above $1,000 per share in late 2025. Despite decades of selling, Lilly Endowment remains a significant shareholder due to the stock’s price appreciation outpacing the foundation’s sell rate.

What to Watch

• Lilly Endowment’s quarterly Form 4 filings for continued systematic selling
• Eli Lilly’s GLP-1 market share trajectory and pipeline updates
• Whether the foundation’s LLY concentration continues to decrease or stabilizes